US medical devices industry sees a rise of 5.4% in deal activity in July 2019

23 August 2019 (Last Updated August 23rd, 2019 10:19)

US medical devices industry sees a rise of 5.4% in deal activity in July 2019

The US medical devices industry saw a rise of 5.4% in overall deal activity during July 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 78 deals worth $5.82bn were announced in July 2019, compared to the 12-month average of 74 deals.

Venture financing was the leading category in the month in terms of volume with 50 deals which accounted for 64.1% of all deals.

In second place was M&A with 22 deals, followed by private equity with six transactions, respectively accounting for 28.2% and 7.7% of overall deal activity in the country’s medical devices industry during the month.

In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $5bn, while venture financing and private equity deals totalled $540.5m and $284.1m, respectively.

US medical devices industry deals in July 2019: Top deals

The top five medical devices industry deals accounted for 87.1% of the overall value during July 2019.

The combined value of the top five medical devices deals stood at $5.07bn, against the overall value of $5.82bn recorded for the month.

The top five medical devices industry deals of July 2019 tracked by GlobalData were:

1) Exact Sciences’ $2.8bn acquisition of Genomic Health

2) The $1.17bn acquisition of BioTek Instruments by Agilent Technologies

3) Cantel Medical’s $775m acquisition of Hu-Friedy Manufacturing

4) The $170m private equity deal with Aspen Surgical Products by Audax Private Equity

5) American Cancer Society, Andreessen Horowitz, Data Collective Venture Capital, Verily Life Sciences, GV Management Co, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Section 32 and T. Rowe Price Associates’ venture financing of Freenome for $160m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.